









Markets
/
Stocks
/
nasdaq-rare
/

Ultragenyx Pharmaceutical Inc

RARE

24.700USD

+0.910+3.83%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.38BMarket Cap

LossP/E TTM



Ultragenyx Pharmaceutical Inc

24.700

+0.910+3.83%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ultragenyx Pharmaceutical Inc

Currency: USD Updated: 2026-02-06

Key Insights

Ultragenyx Pharmaceutical Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 58 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 65.55.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ultragenyx Pharmaceutical Inc's Score

Industry at a Glance

Industry Ranking

58 / 159

Overall Ranking

168 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Ultragenyx Pharmaceutical Inc Highlights

StrengthsRisks

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 54.19% year-on-year.

Overvalued

The company’s latest PE is -4.17, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 100.97M shares, decreasing 1.39% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 59.28K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.41.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

65.550

Target Price

+165.38%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Ultragenyx Pharmaceutical Inc is 7.46, ranking 113 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 159.93M, representing a year-over-year increase of 14.65%, while its net profit experienced a year-over-year increase of 35.12%.

Score

Industry at a Glance

Previous score

7.46

Change



Financials

4.75

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.98

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.31

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Ultragenyx Pharmaceutical Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Ultragenyx Pharmaceutical Inc is 6.12, ranking 133 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -4.17, which is -20.16% below the recent high of -3.33 and -118.18% above the recent low of -9.09.

Score

Industry at a Glance

Previous score

6.12

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 58/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Ultragenyx Pharmaceutical Inc is 8.57, ranking 25 out of 159 in the Pharmaceuticals industry. The average price target is 78.50, with a high of 128.00 and a low of 35.00.

Score

Industry at a Glance

Previous score

8.57

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

65.550

Target Price

+165.38%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Ultragenyx Pharmaceutical Inc

RARE

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Ultragenyx Pharmaceutical Inc is 6.89, ranking 98 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 26.35 and the support level at 22.53, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.57

Change

0.32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.839

Neutral

RSI(14)

46.794

Neutral

STOCH(KDJ)(9,3,3)

49.812

Neutral

ATR(14)

1.020

High Vlolatility

CCI(14)

48.795

Neutral

Williams %R

29.319

Buy

TRIX(12,20)

-0.496

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

24.548

Buy

MA10

24.445

Buy

MA20

23.925

Buy

MA50

28.557

Sell

MA100

30.192

Sell

MA200

31.704

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Ultragenyx Pharmaceutical Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 104.66%, representing a quarter-over-quarter increase of 3.73%. The largest institutional shareholder is The Vanguard, holding a total of 10.24M shares, representing 10.62% of shares outstanding, with 0.62% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

10.11M

-0.79%

BlackRock Institutional Trust Company, N.A.

5.07M

+1.09%

Fidelity Management & Research Company LLC

3.92M

+72.84%

Sands Capital Management, LLC

Star Investors

3.77M

-4.40%

State Street Investment Management (US)

3.69M

+43.55%

RTW Investments L.P.

3.26M

+90.83%

JP Morgan Asset Management

3.25M

+24.74%

Fidelity Institutional Asset Management

3.36M

+906.25%

Baker Bros. Advisors LP

2.77M

Kakkis (Emil D)

2.69M

-1.17%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ultragenyx Pharmaceutical Inc is 3.64, ranking 101 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.15. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.